Acute Kidney Injury in Children

Brian Stotter, MD, FAAP
Assistant Professor of Pediatrics
Washington University School of Medicine
St. Louis, MO
Disclaimer

- Statements and opinions expressed are those of the author and not necessarily those of the American Academy of Pediatrics (AAP).

- Mead Johnson sponsors programs such as this to give healthcare professionals access to scientific and educational information provided by experts. The presenter has complete and independent control over the planning and content of the presentation, and is not receiving any compensation from Mead Johnson for this presentation. The presenter’s comments and opinions are not necessarily those of Mead Johnson. In the event that the presentation contains statements about uses of drugs that are not within the drugs' approved indications, Mead Johnson does not promote the use of any drug for indications outside the FDA-approved product label.
Learning Objectives

- Formulate a differential diagnosis for causes of acute kidney injury (AKI) based on clinical and laboratory findings.

- Describe the initial management of AKI and recall the indications for renal replacement therapy.

*Figures for this presentation, unless otherwise noted, were created by Brian Stotter, MD, FAAP on behalf of the AAP Section on Nephrology (SONp) Executive Committee.*
A 38-week gestational age male infant is delivered via C-section for fetal distress. He requires PPV, intubation, and chest compressions in the delivery room.

APGARs are 3, 6, and 7 at 1, 5, and 10 minutes respectively. After resuscitation he remains hypotensive and requires IV fluids, packed RBCs, and is started on dopamine.
On day of life 2 he becomes oliguric, edematous, and poorly responds to a trial of furosemide. His birth weight was 3.2 kg and his current weight is 3.7 kg. His length is 50.8 cm. Labs are notable for hyperkalemia with potassium 6.7 mmol/L, BUN 13 mg/dL, and creatinine 1.4 mg/dL.

How would you assess his current kidney function?

How would you manage this patient?
Definitions of AKI

- Abrupt loss of renal function that results in the kidneys’ inability to maintain homeostasis
- Anuria – no urine production
- Oliguria – urine production less than 0.5 mL/kg/hr or less than 300 mL/m²/day
- Non-oliguria – urine production greater than 0.5 mL/kg/hr
Comparison of AKI Criteria

<table>
<thead>
<tr>
<th>Table 1</th>
<th>Acute kidney injury classification criteria</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Stage</th>
<th>SCr-Based</th>
<th>Urine Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>Risk</td>
<td>&gt;25% eCCl decrease</td>
<td>&lt;0.5 mL/kg/h for 8 h</td>
</tr>
<tr>
<td>Injury</td>
<td>&gt;50% eCCl decrease</td>
<td>&lt;0.5 mL/kg/h for 16 h</td>
</tr>
<tr>
<td>Failure</td>
<td>&gt;75% eCCl decrease OR</td>
<td>OR &lt;35 mL/min/1.73 m² for 12 h</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage</th>
<th>SCr-Based</th>
<th>Urine Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>SCr increase ≥0.3 mg/dL OR 150%–200% in &lt;48 h</td>
<td>&lt;0.5 mL/kg/h for 8 h</td>
</tr>
<tr>
<td>II</td>
<td>SCr increase 200%–300%</td>
<td>&lt;0.5 mL/kg/h for 16 h</td>
</tr>
<tr>
<td>III</td>
<td>SCr increase 200%–300% OR SCr &gt;4.0 mg/dL OR if &lt;18 y of age then eCCl &lt;35 mL/min/1.73 m²</td>
<td>&lt;0.5 mL/kg/h for 24 h</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Stage</th>
<th>SCr-Based</th>
<th>Urine Output</th>
</tr>
</thead>
<tbody>
<tr>
<td>I</td>
<td>SCr increase ≥0.3 mg/dL in 48 h OR 1.5–1.9 times</td>
<td>&lt;0.5 mL/kg/h for 6–12 h</td>
</tr>
<tr>
<td>II</td>
<td>SCr increase 2.0–2.9 times</td>
<td>&lt;0.5 mL/kg/h for 12 h</td>
</tr>
<tr>
<td>III</td>
<td>SCr &gt;3.0 increase OR SCr &gt; 4.0 mg/dL OR if &lt;18 y of age then eCCl &lt;35 mL/min/1.73 m²</td>
<td>&lt;0.5 mL/kg/h for 24 h</td>
</tr>
</tbody>
</table>

Abbreviations: AKIN, Acute Kidney Injury Network; eCCl, estimated creatinine clearance; KDIGO, Kidney Disease Improving Global Outcomes; pRIFLE, pediatric version of the RIFLE criteria (Risk, Injury, Failure, and 2 outcome criteria, Loss and End-Stage Kidney Disease); SCr, serum creatinine.

Who Gets AKI?

- Occurs in 0.39%–1% of all pediatric hospital admissions.
- 34.5% of admissions with AKI require ICU level care.
- Mortality rate 15.3% in all hospitalizations complicated by AKI, compared to 0.6% in non-AKI hospitalizations.
- Mortality rate 27.1% for children with AKI requiring renal replacement therapy, 32.8% for children requiring ICU-level care.
- Incidence of CKD (GFR <90 mL/min/1.73m²) up to 6.5 years after AKI event approaches 28% (*BMC Nephrol*. 2014;15:184).
Who Gets AKI?

- The most common causes of AKI vary based on clinical setting.
  - Community – moderate/severe dehydration, glomerulonephritis, HUS
  - Hospital – sepsis, nephrotoxic medications, cardiac surgery, bone marrow or solid organ transplantation
    - 20%–40% of post-op cardiac patients develop some degree of AKI
Why Does AKI Occur?

- There can be overlap and multiple contributors for a single AKI event.
- What factors could have contributed to our newborn’s AKI?
Pre-Renal

- Injury related to decreased renal perfusion
  - Hypovolemia (e.g. gastroenteritis, hemorrhage)
  - Hypotension (e.g. shock)
  - Hypoxia (e.g. birth asphyxia)
  - Hepatic failure/hepatorenal syndrome
  - Third spacing (e.g. hypoalbuminemia, nephrotic syndrome)
  - Cardiac dysfunction
  - Sepsis
  - Medications (e.g. NSAIDs)
  - Renovascular disease (e.g. thrombus)
# Renal/Intrinsic

<table>
<thead>
<tr>
<th>Glomerular</th>
<th>Vascular</th>
<th>Tubular/Interstitial</th>
</tr>
</thead>
<tbody>
<tr>
<td>Post-infectious GN</td>
<td>TMA/HUS</td>
<td>ATN</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Following pre-renal factors or nephrotoxic medications</td>
</tr>
<tr>
<td>IgA nephropathy</td>
<td>Vasculitis (HSP, IgA)</td>
<td>Interstitial nephritis</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Drug allergy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Viral infection</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Autoimmune</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Pyelonephritis</td>
</tr>
<tr>
<td>SLE nephritis</td>
<td>Renal artery stenosis</td>
<td></td>
</tr>
<tr>
<td>ANCA vasculitis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Post-Renal

- Injury related to obstruction of urine flow
  - Congenital anomalies
    - PUV
    - UPJ and UVJ obstruction
  - Acquired
    - Stones
    - Tumors and masses
History/Physical Exam

- Is fluid overload present (big risk factor for mortality)?
- Is there hemodynamic instability (may suggest poor renal perfusion)?
- Any recent nephrotoxic medications or toxic exposures?
  - NSAIDs, aminoglycosides, chemotherapy
  - Contrast agents
- Is there a history of an abnormal voiding pattern?
- Any findings to suggest a systemic disease process?
  - Rash or joint pain (HSP, SLE nephritis, ANCA vasculitis)
Assessment

- Varies depending on clinical scenario and suspected cause(s)
- At a minimum
  - CBC, electrolytes, BUN, creatinine, calcium, phosphorus
  - Urinalysis with microscopy
    - Sediment may provide clues to etiology (e.g. RBC casts in glomerulonephritis, “muddy brown” casts in ATN)
- Urine indices (e.g. urine sodium) may help distinguish pre-renal AKI from ATN in oliguric patients
- Imaging
  - Renal/bladder ultrasound
  - CT/MRI as indicated
Fractional Excretion of Sodium

- Kidneys respond to low renal perfusion by increasing sodium reabsorption from the ultrafiltrate to restore volume.

- Fractional excretion of sodium ($FE_{Na}$) can be used to distinguish pre-renal AKI from ATN in oliguric AKI.
  - <1% in children or <3% in neonates/infants suggests pre-renal.
  - >1% in children or >3% in neonates/infants suggests ATN.

$$FE_{Na} = \frac{U_{Na} \times S_{Cr}}{U_{Cr} \times S_{Na}} \times 100\%$$

- $FE_{Na}$ not valid if diuretics have been used ($FE_{urea}$ can be used instead).
Practice

An 8-year-old boy has oliguric AKI from sepsis. His serum labs show sodium 126 mmol/L, potassium 5.8 mmol/L, chloride 102 mmol/L, bicarbonate 20 mmol/L, BUN 97 mg/dL, creatinine 3.5 mg/dL. His urine labs show a urine sodium 118 mmol/L, urine creatinine 41 mg/dL.

What is his $\text{FE}_{\text{Na}}$?

\[
\text{FE}_{\text{Na}} = \frac{U_{\text{Na}} \times S_{\text{Cr}}}{U_{\text{Cr}} \times S_{\text{Na}}} \times 100\%
\]

\[
= \frac{(118)(3.5)}{(41)(126)} \times 100\%
\]

\[
\text{FE}_{\text{Na}} = 8.0\%
\]
Management

- Treat or remove the underlying cause.
- Adjust current medication dosing based on estimated GFR (may be inaccurate in AKI).
  - Bedside Schwartz equation
    - \( \text{eGFR (mL/min/1.73m}^2) = 0.413 \times \frac{\text{height (cm)}}{S_{\text{Cr}}} \)
- Optimize renal perfusion while minimizing fluid overload.
Management

- Electrolytes
  - Hyperkalemia
    - **Calcium gluconate** – stabilize cardiac membranes
    - No potassium-containing fluids
    - Cation exchange resin – sodium polystyrene sulfonate
    - Diuretics
    - For emergent hyperkalemia treatment, use albuterol or insulin + IV dextrose to promote intracellular $K^+$ shift
  - Hyperphosphatemia
    - Phosphate binders, especially if severe and associated with hypocalcemia (calcium carbonate)
Management

- **Metabolic acidosis**
  - Treat reversible causes and improve renal perfusion when possible (e.g. volume depletion, lactic acidosis).
  - May need renal replacement therapy for severe acidosis refractory to conservative management.
  - Caution: rapid correction of acidosis may lower ionized calcium and lead to symptomatic hypocalcemia.

- **Hypertension**
  - Diuretics often helpful for hypertension in AKI related to volume expansion and fluid overload.
  - Calcium channel blockers (e.g. amlodipine, isradipine) and beta blockers (e.g. labetalol) frequently used.
  - Avoid ACE inhibitors and ARBs, as these may worsen GFR.
Common Indications for Renal Replacement Therapy

- Fluid overload refractory to diuretics or associated with respiratory compromise
- Refractory hyperkalemia or metabolic acidosis
- Uremia (altered mental status, seizures, pericarditis, bleeding diathesis)
- AKI in the setting of a known dialyzable toxin (e.g. ethylene glycol)
Back to our patient...

On day of life 2 he becomes oliguric, edematous, and poorly responds to a trial of furosemide. His birth weight was 3.2 kg and his current weight is 3.7 kg. His length is 50.8 cm. Labs are notable for hyperkalemia with potassium 6.7 mmol/L, BUN 13 mg/dL, and creatinine 1.4 mg/dL.

How would you assess his current kidney function?

How would you manage this patient?
How would you manage this patient?

- eGFR = 0.413 x height (cm)/Scr = (0.413 x 50.8)/1.4 = 15 mL/min/1.73m²
- Adjust medication dosing to eGFR
- Avoid further nephrotoxic insults (medications, contrast)
- BSA is approx. 0.23 m², limit fluid to insensibles (300 mL/m²/day = 69 mL/day) plus replacement for ongoing losses
- 24 hr fluid goal: net negative fluid balance (baby is above birth weight and edematous)
  - May consider an increased dose of furosemide or other diuretics
- For hyperkalemia, give calcium gluconate for cardioprotection (especially if EKG changes are present), remove potassium in IV fluids/TPN, consider sodium polystyrene sulfonate (cautious in neonates)
Further Reading


Post-Webinar Evaluation Survey

Thank you for participating in the Pediatric Nephrology on the Go curriculum. We value your feedback—your responses to this survey (www.surveymonkey.com/r/BDZRRMY) will assist the SONp in assessing the impact of the presentation, improving the quality of the content, and identifying future topics to better serve you and the greater pediatrics community. The survey should take 2–3 minutes and your responses are confidential.
Visit *Pediatric Care Online* today for additional information on this and other topics.

http://pediatriccare.solutions.aap.org

*Pediatric Care Online* is a convenient electronic resource for immediate expert help with virtually every pediatric clinical information need with must-have resources that are included in a comprehensive reference library and time-saving clinical tools.

Don’t have a subscription to PCO?  
Then take advantage of a free trial today!

http://pediatriccare.solutions.aap.org/SS/Free_Trial.aspx